Recommended

New Webinar: Neurological disorders – organoids for early drug discovery
Listen to our latest podcast: breaking resistance – the future of immunotherapy in oncology
Download now: The latest advancements and breakthroughs in immuno-oncology
Register now: Ion Channel Drug Discovery – Recent Advances in Novel Non-Opioid Pain Research
Register now: SAFIRE: AI predicted ADME for drug discovery: leveraging bioprint
On demand webinar

Advancing therapeutics targeting cytokines with functional cell-based assays

Watch this webinar to discover functional cell-based assays for characterizing novel therapeutics & biosimilars targeting cytokines in inflammation & oncology.

Cytokines

Register to watch this webinar discussion for free

Therapeutics targeting inflammatory cytokines that produce Th17- or Th2- (helper T cells) mediated immune responses have demonstrated significant clinical impact in several diseases, including psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, asthma, & atopic dermatitis. Several important agents inhibiting Th17 immune responses, including approved drugs such as risankizumab & guselkumab, target IL-23, while others, like secukinumab, target IL-17. In the Th2 pathway, the anti-IL-4/IL-13 antibody dupilumab has been successfully employed for the treatment of asthma & atopic dermatitis, with many other indications still under evaluation. Eurofins DiscoverX has established a portfolio of cell-based assays to aid in the characterization of therapeutics targeting these important cytokines utilizing the PathHunter® enzyme fragment complementation technology.

In this on-demand webinar, we share case studies on the use of cell-based assays that monitor receptor dimerization or pathway activation (e.g. transcriptional reporters) targeting IL-23, IL-12, IL-17, & IL-4/IL-13 for a variety of applications, including rank ordering of antibodies, evaluating antibody specificity, as well as detection of anti-drug neutralizing antibodies.

Data demonstrating the suitability of these assays for determining relative potency to support lot-release applications during manufacture & drug product release will also be shared. Finally, new assays targeting emerging therapeutic targets for inflammation, such as IL-7 & TSLP, will be highlighted.

Key learning points

  • Review key cytokines involved in inflammatory diseases & examples of clinically successful marketed therapeutics targeting these cytokines
  • Examine case studies highlighting the application of various cell-based assay formats to assess the mechanism of action of antibodies targeting existing & emerging cytokine targets in inflammatory disease
  • Understand optimal assay formats for assessing antibody specificity vs successful detection of neutralizing antibodies in cell-based assays
  • Learn about the breadth of PathHunter cytokine assays available for characterization of novel therapeutics & biosimilars targeting cytokines in inflammation & oncology.

Download now.

SPEAKER

CytokinesJennifer Lin-Jones, Ph.D, Associate Director of Assay Development R&D Department, Eurofins DiscoverX

Dr. Jennifer Lin-Jones is Associate Director of Assay Development at Eurofins DiscoverX where she has been a major contributor in novel cell-based assay and tool development to support the expansive Eurofins DiscoverX assay portfolio as well as assays for client-focused projects.  Jennifer received her B.S. from MIT, Ph.D. in Zoology from the University of Washington and was a post-doc at University of California, Berkeley.

 

FAQs

FAQs

Is the webinar free? 

Yes – there is no charge to watch the webinar, either live or on-demand. 

Can I watch it later? 

The webinar is now available to watch on-demand. 

How long will the webinar be? 

This webinar lasts up to an hour. 

What do I need to watch this webinar? 

All you need is a computer with an internet connection. We recommend using headphones if possible if you’re in an office environment.